AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17362252 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE determination and BAT using recombinant allergens (rPru p 3)
Number of subjects: 30
Study 17362252 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and recombinant plant allergens
Number of subjects: 30
Study 15070938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 9
Study 15070938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 11317472 — intervention group
Group type: EXPERIMENTAL
Intervention: MPPG (3 x 150 mg daily)
Number of subjects: 0
Study 11317472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9240606 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control and tertiary level obstetric care
Number of subjects: 300
Study 9240606 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetric care
Number of subjects: 300
Study 8496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release propranolol (mean 293 mg/day)
Number of subjects: 50
Study 8496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release diltiazem (mean 350 mg/day)
Number of subjects: 50
Study 8496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean 79 mg/day)
Number of subjects: 50
Study 8496526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8496526 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications (overall)
Number of subjects: 50
Study 2967183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol (B)
Number of subjects: 87
Study 2967183 — intervention group
Group type: COMPARATOR
Intervention: 100 mg metoprolol (M)
Number of subjects: 87
Study 30380020 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Embedded Dynamic Treatment Regime (EDTR)
Number of subjects: 0
Study 30380020 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation method for power analysis
Number of subjects: 0
Study 30380020 — intervention group
Group type: EXPERIMENTAL
Intervention: Extending Treatment Effectiveness of Naltrexone (EXTEND) trial
Number of subjects: 0
Study 31269457 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy snacks
Number of subjects: 100
Study 31269457 — intervention group
Group type: COMPARATOR
Intervention: Healthy snacks
Number of subjects: 100
Study 28842597 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (3 hours sleep)
Number of subjects: 53
Study 25854443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 µg and etomidate 0.1 mg/kg
Number of subjects: 52
Study 25854443 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.1 mg/kg
Number of subjects: 52
Study 23871500 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective hospital admission
Number of subjects: 60
Study 23871500 — intervention group
Group type: COMPARATOR
Intervention: Non-admitted group (control)
Number of subjects: 60
Study 21481280 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/Vinorelbine (EPI/VNB) - EPI 90 mg/m2 on day 1, VNB 25 mg/m2 on days 1,5 plus G-CSF subcutaneously on days 7-12, cycles every 21 days
Number of subjects: 104
Study 21481280 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin/Vinorelbine (PLD/VNB) - PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, cycles every 4 weeks
Number of subjects: 104
Study 19111215 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed fluid irrigation (37 degrees C to 39 degrees C)
Number of subjects: 50
Study 19111215 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature fluid irrigation
Number of subjects: 50
Study 16414394 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment with a wavelength of 980 nm
Number of subjects: 51
Study 16414394 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment with a wavelength of 810 nm
Number of subjects: 51
Study 16414394 — intervention group
Group type: COMPARATOR
Intervention: Both groups (980 nm and 810 nm)
Number of subjects: 51
Study 15295150 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality therapy using a laptop PC, joystick, VR helmet, and specially-designed CD-ROM programs (Virtools) for 12 sessions over 25 weeks
Number of subjects: 30
Study 15295150 — intervention group
Group type: COMPARATOR
Intervention: Control group using an old VR helmet and PC Pentium 133 16 Mb RAM for the same therapeutic protocol
Number of subjects: 30
Study 15295150 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy alone
Number of subjects: 30
Study 11374677 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (t1/2 > 192 min) in functional dyspepsia
Number of subjects: 798
Study 11374677 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (t1/2 > 192 min) in type I diabetes
Number of subjects: 798
Study 11374677 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper GI symptoms in patients with delayed gastric emptying
Number of subjects: 798
Study 11374677 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom prevalence and severity
Number of subjects: 798
Study 9747408 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 24
Study 9747408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8147337 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling to increase dietary calcium through food consumption to 1500 mg/d (n = 106)
Number of subjects: 326
Study 8147337 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐mg/d calcium supplement (n = 109)
Number of subjects: 326
Study 8147337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 111)
Number of subjects: 326
Study 2894546 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin assay
Number of subjects: 473
Study 2894546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteraemia
Number of subjects: 473
Study 29124381 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEBDOX-TACE)
Number of subjects: 10
Study 29124381 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced multidetector CT (MDCT)
Number of subjects: 10
Study 26577034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (2 g)
Number of subjects: 48
Study 26577034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25913660 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (below‐elbow thumb spica cast until radiological signs of union appeared)
Number of subjects: 38
Study 25913660 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (wrist arthroscopy and percutaneous antegrade screw fixation)
Number of subjects: 38
Study 22841455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 96
Study 22841455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol
Number of subjects: 96
Study 22841455 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol (control)
Number of subjects: 96
Study 22841455 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of alcohol (0.4 g/kg and 0.6 g/kg)
Number of subjects: 96
Study 21491487 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 10000
Study 21491487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 18652273 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (atraumatic restorative treatment) approach using Ketac‐Molar (3M ESPE) ionomer cement
Number of subjects: 58
Study 16867057 — intervention group
Group type: EXPERIMENTAL
Intervention: ECoScreen
Number of subjects: 30
Study 16867057 — intervention group
Group type: COMPARATOR
Intervention: RTube
Number of subjects: 30
Study 12751480 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 7
Study 12751480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11098947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic-pneumatic band system (HB-CPR)
Number of subjects: 0
Study 11098947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic vest system (PV-CPR)
Number of subjects: 0
Study 11098947 — intervention group
Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 0
Study 8817136 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia buffered with bicarbonate (St Thomas' II solution)
Number of subjects: 20
Study 8817136 — intervention group
Group type: EXPERIMENTAL
Intervention: Non buffered crystalloid cardioplegia enriched with glutamate and mannitol (Menasché's solution)
Number of subjects: 20
Study 2073061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole foam (2%); applied once
Number of subjects: 61
Study 2073061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excipient); applied once
Number of subjects: 61
Study 7023597 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastibell device
Number of subjects: 100
Study 7023597 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 100
Study 31856990 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone corneal shield
Number of subjects: 25
Study 31856990 — intervention group
Group type: COMPARATOR
Intervention: Conventional bandage contact lens (BCL)
Number of subjects: 25
Study 28414516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid
Number of subjects: 85
Study 28414516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk
Number of subjects: 85
Study 28414516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's odor
Number of subjects: 85
Study 28414516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 25910930 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (EA) applied at ST36 and GB34 for 30 min on the first two postoperative days, also receiving PCA
Number of subjects: 47
Study 25910930 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-point EA identical to EAG except given 1 cm lateral to ST36 and GB34, also receiving PCA
Number of subjects: 47
Study 25910930 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) using only patient-controlled analgesia (PCA)
Number of subjects: 47
Study 23223595 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 606
Study 23223595 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 606
Study 23223595 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 606
Study 23223595 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 606
Study 21670072 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostatic mixer valves (TMVs) installed in social housing
Number of subjects: 1
Study 21670072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of TMVs
Number of subjects: 1
Study 19114438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume Dysport (500 U/5 mL)
Number of subjects: 22
Study 19114438 — intervention group
Group type: COMPARATOR
Intervention: Low-volume Dysport (500 U/1 mL)
Number of subjects: 22
Study 16776749 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 150
Study 15025796 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU 300 mg/m2 daily + mitomycin-C 7 mg/m2 every 6 weeks
Number of subjects: 320
Study 15025796 — intervention group
Group type: COMPARATOR
Intervention: Circadian-timed infusion (CTI) of 5-FU starting at 600 mg/m2, reduced to 450 mg/m2 + mitomycin-C 7 mg/m2 every 6 weeks
Number of subjects: 320
Study 15025796 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU + mitomycin-C
Number of subjects: 320
Study 15025796 — intervention group
Group type: COMPARATOR
Intervention: CTI 5-FU + mitomycin-C
Number of subjects: 320
Study 15025796 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI 5-FU
Number of subjects: 320
Study 11561260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine 60 microg/kg/min
Number of subjects: 25
Study 11561260 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study 9489592 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg alone
Number of subjects: 12
Study 9489592 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone 400 mg with cholestyramine 12 g
Number of subjects: 12
Study 8181888 — intervention group
Group type: EXPERIMENTAL
Intervention: oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t.i.d.)
Number of subjects: 87
Study 8181888 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin plus quinidine (total dose, 1350 mg)
Number of subjects: 87
Study 8181888 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study 2967304 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 alpha‐fludrocortisone acetate (9 alpha F; 0.6 mg/day)
Number of subjects: 8
Study 2967304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg/day)
Number of subjects: 8
Study 2967304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31690105 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2 mg)
Number of subjects: 48
Study 31690105 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 48
Study 30200106 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 144
Study 30200106 — intervention group
Group type: COMPARATOR
Intervention: Point-of-care (POC) glucose measurement (Control group)
Number of subjects: 144
Study 26484407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting IGFBP-1
Number of subjects: 77
Study 26484407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of IGFBP-1 to fasting insulin
Number of subjects: 77
Study 26484407 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 at time zero
Number of subjects: 77
Study 26484407 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment-insulin resistance
Number of subjects: 77
Study 26484407 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected insulin release at the glucose peak (CIRgp)
Number of subjects: 77
Study 24942282 — intervention group
Group type: EXPERIMENTAL
Intervention: High facilitation and action learning
Number of subjects: 38
Study 24942282 — intervention group
Group type: COMPARATOR
Intervention: Standard Gold Standards Framework facilitation
Number of subjects: 38
Study 24141750 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement during fusional vergence testing
Number of subjects: 50
Study 24141750 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing order (convergence followed by divergence)
Number of subjects: 50
Study 24141750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue assessment
Number of subjects: 50
Study 19946869 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in group format for informal carers
Number of subjects: 292
Study 18538047 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 40
Study 18538047 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 40
Study 16091912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine ointment (n=32) every 8 h for 8 weeks
Number of subjects: 64
Study 16091912 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (n=32)
Number of subjects: 64
Study 12655529 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 120
Study 12655529 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 120
Study 12655529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 120
Study 10798453 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized music for 6 weeks followed by classical 'relaxation' music for 6 weeks (30 minutes, two times per week)
Number of subjects: 39
Study 10798453 — intervention group
Group type: COMPARATOR
Intervention: Classical 'relaxation' music for 6 weeks followed by individualized music for 6 weeks (30 minutes, two times per week)
Number of subjects: 39
Study 9003975 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-3
Number of subjects: 100
Study 9003975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1350407 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Number of subjects: 26
Study 1350407 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Number of subjects: 26
Study 2938614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g day‐1) with R warfarin (15 mg)
Number of subjects: 8
Study 2938614 — intervention group
Group type: COMPARATOR
Intervention: Warfarin enantiomers (15 mg) alone
Number of subjects: 8
Study 30053967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100 [200]/25 μg
Number of subjects: 0
Study 30053967 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 26482723 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with cisplatin plus concurrent chemoradiotherapy (SCCC)
Number of subjects: 144
Study 26482723 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus concurrent chemoradiotherapy (CCC)
Number of subjects: 144
Study 25518574 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week rehabilitation program (Group I, 19 patients, mean age 59.2 ± 8.3 years)
Number of subjects: 69
Study 25518574 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program (Group II, 29 patients, mean age 55.3 ± 7.9 years)
Number of subjects: 69
Study 25518574 — intervention group
Group type: COMPARATOR
Intervention: Modified rehabilitation program (Group III, reference group, 21 patients, mean age 65.4 ± 8.2 years)
Number of subjects: 69
Study 22951813 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 2046
Study 22951813 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid (ZA)
Number of subjects: 2046
Study 20563879 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and physical program (brief shoulder and neck exercises, relaxation exercise, instructions on reducing parafunction and hyperfunction)
Number of subjects: 192
Study 20563879 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and physical program
Number of subjects: 192
Study 18460401 — intervention group
Group type: EXPERIMENTAL
Intervention: gel‐to‐foam dentifrice
Number of subjects: 34
Study 18460401 — intervention group
Group type: COMPARATOR
Intervention: control dentifrice
Number of subjects: 34
Study 17177905 — intervention group
Group type: EXPERIMENTAL
Intervention: Active referral 1: specialist referral with four CISS outcalls (1 week, 6 weeks, 3 months, 6 months post diagnosis)
Number of subjects: 100
Study 17177905 — intervention group
Group type: EXPERIMENTAL
Intervention: Active referral 2: specialist referral with one CISS outcall (1 week post diagnosis)
Number of subjects: 100
Study 17177905 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive referral: specialist recommended patient contacts CISS at their initiative
Number of subjects: 100
Study 12956346 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion treatment
Number of subjects: 32
Study 12956346 — intervention group
Group type: COMPARATOR
Intervention: Control slides (no treatment)
Number of subjects: 32
Study 10715523 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAS4 hepatitis B vaccine
Number of subjects: 150
Study 10715523 — intervention group
Group type: COMPARATOR
Intervention: Engerix‐B(TM)
Number of subjects: 150
Study 10715523 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine with alternative formulation on alum
Number of subjects: 150
Study 8856383 — intervention group
Group type: EXPERIMENTAL
Intervention: Blister suction technique
Number of subjects: 15
Study 8856383 — intervention group
Group type: COMPARATOR
Intervention: Wick technique
Number of subjects: 15
Study 1622916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous ritodrine (0.2 mg/min) in cervical cerclage group
Number of subjects: 117
Study 1622916 — intervention group
Group type: COMPARATOR
Intervention: Oral ritodrine (60 mg/day) in amniocentesis group
Number of subjects: 117
Study 1622916 — intervention group
Group type: COMPARATOR
Intervention: No ritodrine treatment in both groups
Number of subjects: 117
Study 6135344 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (timolol)
Number of subjects: 0
Study 6135344 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (metoprolol)
Number of subjects: 0
Study 6135344 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (chronic therapy)
Number of subjects: 0
Study 30883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (at least 6 months)
Number of subjects: 5989
Study 30883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (>3 years)
Number of subjects: 5989
Study 30883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (6 months to 3 years)
Number of subjects: 5989
Study 30577872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based sexual and reproductive health services awareness and delivery application
Number of subjects: 0
Study 27224505 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein and creatine co-supplementation (WHEY+CR)
Number of subjects: 0
Study 27224505 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation (WHEY)
Number of subjects: 0
Study 24552755 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane Ultra lubricant eye drops (applied twice a day for 2 weeks)
Number of subjects: 89
Study 24552755 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 89
Study 22746398 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor ETS exposure (Group 2)
Number of subjects: 97
Study 22746398 — intervention group
Group type: COMPARATOR
Intervention: No indoor ETS exposure (Group 1)
Number of subjects: 97